A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene

Leukemia

Volumn 27, Issue 1, 2013, Pages 245-248

  Fasan, A ^a   Haferlach, C ^a   Alpermann, T ^a   Kern, W ^a   Haferlach, T ^a   Schnittger, S ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DNA; FANCONI ANEMIA GROUP L PROTEIN; FLT3 LIGAND; HLA DR ANTIGEN; NSD1 PROTEIN; NUCLEOPHOSMIN; NUCLEOPORIN 98; PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA7; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL RENEWAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 11P; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CYTOGENETICS; FUSION GENE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; LETTER; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873570235     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.230     Document Type: Letter

References (15)

1. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80: 2191-2198.
2. Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112: 118-126.
3. Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D et al. Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998; 103: 72-78.
4. Slape C, Aplan PD. The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma 2004; 45: 1341-1350.
5. Huang N, vom BE, Garnier JM, Lerouge T, Vonesch JL, Lutz Y et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 1998; 17: 3398-3412.
6. Kurotaki N, Harada N, Yoshiura K, Sugano S, Niikawa N, Matsumoto N. Molecular characterization of NSD1, a human homologue of the mouse Nsd1 gene. Gene 2001; 279: 197-204.
7. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804-812.
8. Hollink IH, Van den Heuvel-Eibrink MM, rentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118: 3645-3656.
9. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
10. Chou WC, Chen CY, Hou HA, Lin LI, Tang JL, Yao M et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia 2009; 23: 1303-1310.
11. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006; 20: 1295-1297.
12. Taketani T, Taki T, Nakamura T, Kobayashi Y, Ito E, Fukuda S et al. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia 2010; 24: 1975-1977.
13. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897-1909.
14. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961-2968.
15. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380.